Back

Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis

Stillger, M. N.; Chen, C.-Y.; Lai, Z. W.; Li, M.; Schaefer, A.; Pagenstecher, A.; Nimsky, C.; Bartsch, J. W.; Schilling, O.

2022-10-20 cancer biology
10.1101/2022.10.19.511526 bioRxiv
Show abstract

BackgroundGlioblastoma multiforme (GBM) is characterized by an unfavorable prognosis for patients affected. During standard-of-care chemotherapy using temozolomide (TMZ), tumors acquire resistance thereby causing tumor recurrence. Thus, deciphering essential molecular pathways causing TMZ resistance are of high therapeutic relevance. MethodsMass spectrometry based proteomics were used to study the GBM proteome. Immunohistochemistry staining of human GBM tissue for either calpain-1 or -2 was performed to locate expression of proteases. In vitro cell based assays were used to measure cell viability and survival of primary patient-derived GBM cells and established GBM cell lines after TMZ +/- calpain inhibitor administration. shRNA expression knockdowns of either calpain-1 or calpain-2 were generated to study TMZ sensitivity of the specific subunits. The Comet assay and {gamma}H2AX signal measurements were performed in order to assess the DNA damage amount and recognition. Finally, quantitative real-time PCR of target proteins was applied to differentiate between transcriptional and post-translational regulation. ResultsCalcium-dependent calpain proteases, in particular calpain-2, are more abundant in glioblastoma compared to normal brain and increased in patient-matched initial and recurrent glioblastomas. On the cellular level, pharmacological calpain inhibition increased the sensitivities of primary glioblastoma cells towards TMZ. A genetic knockdown of calpain-2 in U251 cells led to increased caspase-3 cleavage and sensitivity to neocarzinostatin, which rapidly induces DNA strand breakage. We hypothesize that calpain-2 causes desensitization of tumor cells against TMZ by preventing strong DNA damage and subsequent apoptosis via post-translational TP53 inhibition. Indeed, proteomic comparison of U251 control vs. U251 calpain-2 knockdown cells highlights perturbed levels of numerous proteins involved in DNA damage response and downstream pathways affecting TP53 and NF-{kappa}B signaling. TP53 showed increased protein abundance, but no transcriptional regulation. ConclusionTMZ-induced cell death in the presence of calpain-2 expression appears to favor DNA repair and promote cell survival. We conclude from our experiments that calpain-2 expression represents a proteomic mode that is associated with higher resistance via "priming" GBM cells to TMZ chemotherapy. Thus, calpain-2 could serve as a prognostic factor for GBM outcome.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Clinical Epigenetics
53 papers in training set
Top 0.1%
12.7%
2
PLOS ONE
4510 papers in training set
Top 18%
10.3%
3
Neoplasia
22 papers in training set
Top 0.1%
6.9%
4
Cancers
200 papers in training set
Top 0.8%
6.5%
5
Frontiers in Molecular Biosciences
100 papers in training set
Top 0.2%
4.4%
6
Acta Neuropathologica Communications
81 papers in training set
Top 0.1%
4.0%
7
Neuro-Oncology Advances
24 papers in training set
Top 0.1%
4.0%
8
Neuro-Oncology
30 papers in training set
Top 0.2%
3.7%
50% of probability mass above
9
Scientific Reports
3102 papers in training set
Top 35%
3.7%
10
Molecular Oncology
50 papers in training set
Top 0.2%
2.9%
11
Cells
232 papers in training set
Top 1.0%
2.8%
12
Neurobiology of Disease
134 papers in training set
Top 2%
1.9%
13
Frontiers in Oncology
95 papers in training set
Top 2%
1.9%
14
International Journal of Molecular Sciences
453 papers in training set
Top 9%
1.4%
15
Biomolecules
95 papers in training set
Top 1%
1.1%
16
Oncotarget
15 papers in training set
Top 0.2%
1.0%
17
Cell Death Discovery
51 papers in training set
Top 1%
0.9%
18
Biochemistry and Biophysics Reports
28 papers in training set
Top 1%
0.9%
19
Biomedicines
66 papers in training set
Top 2%
0.9%
20
Cell Death & Disease
126 papers in training set
Top 2%
0.8%
21
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 8%
0.8%
22
BMC Cancer
52 papers in training set
Top 2%
0.8%
23
International Journal of Biological Macromolecules
65 papers in training set
Top 3%
0.8%
24
OncoImmunology
22 papers in training set
Top 0.4%
0.8%
25
Journal of the Neurological Sciences
17 papers in training set
Top 0.8%
0.7%
26
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.7%
27
Cancer Letters
32 papers in training set
Top 0.8%
0.7%
28
Diagnostics
48 papers in training set
Top 2%
0.7%
29
Life Sciences
25 papers in training set
Top 2%
0.7%
30
Interface Focus
14 papers in training set
Top 0.4%
0.7%